Medicilon(SH:688202) Xin Lang Zheng Quan·2025-12-23 05:52Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Medisi, indicating a stock price increase of 92.38% year-to-date and a market capitalization of 7.798 billion yuan [2] - Medisi's stock price reached 58.04 yuan per share with a trading volume of 81.93 million yuan and a turnover rate of 1.06% as of December 23 [1] - The company has seen a net inflow of main funds amounting to 1.4455 million yuan, with significant buying and selling activities recorded [1] Group 2 - Medisi's business primarily involves providing comprehensive new drug research services to pharmaceutical companies and other new drug research institutions, with revenue composition being 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research [2] - As of September 30, the number of shareholders increased by 27.83% to 16,500, while the average circulating shares per person decreased by 21.96% to 8,149 shares [2] - For the period from January to September 2025, Medisi achieved an operating income of 843 million yuan, reflecting a year-on-year growth of 5.14%, while the net profit attributable to the parent company was -29.6849 million yuan, showing a significant year-on-year increase of 76.93% [2] Group 3 - Medisi has distributed a total of 158 million yuan in dividends since its A-share listing, with cumulative distributions of 33.9365 million yuan over the past three years [3]